Type Condition

Arlington, TX

213 Clinical Trials near Arlington, TX

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

GHZ339 for Eczema

Arlington, Texas
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

224 Participants Needed

Tibulizumab for Scleroderma

Arlington, Texas
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

80 Participants Needed

Cretostimogene Grenadenorepvec for Bladder Cancer

Arlington, Texas
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

325 Participants Needed

TRK-950 + Ramucirumab + Paclitaxel for Stomach Cancer

Arlington, Texas
This trial is testing a new drug, TRK-950, combined with two existing cancer drugs in patients with a specific type of stomach cancer. The goal is to see if this combination can better control cancer growth and improve survival compared to the existing treatments alone.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

146 Participants Needed

AVD-104 for Age-Related Macular Degeneration

Arlington, Texas
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 90

300 Participants Needed

CIN-102 for Gastroparesis

Arlington, Texas
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: * Screening period (1-2 visits) * Lead-in period (1 visit) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * Drug- CIN-102 Dose 15 mg or 10 mg * Drug- Placebo

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

382 Participants Needed

D-4517.2 for Age-Related Macular Degeneration and Diabetic Macular Edema

Arlington, Texas
This trial tests a new injectable drug, D-4517.2, in people with wet AMD or DME. The drug aims to block a protein that causes harmful blood vessel growth in the eye, potentially preventing further vision loss.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

50 Participants Needed

Saroglitazar Magnesium for Nonalcoholic Fatty Liver Disease with Fibrosis

Arlington, Texas
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

180 Participants Needed

BION-1301 for IgA Nephropathy

Arlington, Texas
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

103 Participants Needed

Dapagliflozin + Baxdrostat for Chronic Kidney Disease

Arlington, Texas
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Prior Safety Data

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

218 Participants Needed

Tulisokibart for Rheumatoid Arthritis

Arlington, Texas
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

182 Participants Needed

AlloNK + Rituximab for Rheumatic Diseases

Arlington, Texas
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

90 Participants Needed

Tulisokibart for Hidradenitis Suppurativa

Arlington, Texas
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

147 Participants Needed

Vicadrostat + Empagliflozin for Chronic Kidney Disease

Arlington, Texas
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease. In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine. The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

416 Participants Needed

ABBV-CLS-628 for Polycystic Kidney Disease

Arlington, Texas
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Around 240 adult participants with ADPKD will be enrolled at approximately 100 sites worldwide. Participants will receive IntraVenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks. Participants will be followed for up to 15 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55

240 Participants Needed

JNJ-95475939 for Atopic Dermatitis

Arlington, Texas
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

240 Participants Needed

RO7790121 for Eczema

Arlington, Texas
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

160 Participants Needed

RO7446603 + Aflibercept/Faricimab for Diabetic Macular Edema

Arlington, Texas
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

546 Participants Needed

AVTX-009 for Hidradenitis Suppurativa

Arlington, Texas
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

250 Participants Needed

Mevidalen for Alzheimer's Disease

Arlington, Texas
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

300 Participants Needed

Why Other Patients Applied

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

VYN201 Gel for Vitiligo

Arlington, Texas
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

200 Participants Needed

Efinopegdutide for Fatty Liver Disease

Arlington, Texas
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

129 Participants Needed

Efinopegdutide for Fatty Liver Disease

Arlington, Texas
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

80 Participants Needed

NNC0194-0499, Cagrilintide, and Semaglutide for Alcoholic Liver Disease

Arlington, Texas
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

270 Participants Needed

Miricorilant for Non-Alcoholic Steatohepatitis

Arlington, Texas
This trial is testing a medication called miricorilant to see if it can help adults with a liver disease called NASH. The medication aims to reduce fat and inflammation in the liver. About 150 patients will take either miricorilant or another treatment for several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

175 Participants Needed

TARA-002 for Bladder Cancer

Arlington, Texas
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF. Participants will be enrolled into one of 2 cohorts: Cohort A: * Participants with CIS (± Ta/T1) who are BCG naive, or * Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis Cohort B: * Participants who are BCG unresponsive
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

131 Participants Needed

DB-1310 for Advanced Cancer

Arlington, Texas
This trial is testing a new drug called DB-1310 to see if it is safe for patients with advanced solid tumors. It will also check if combining DB-1310 with another drug, trastuzumab, helps fight cancer better.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

1000 Participants Needed

AR-14034 for Age-Related Macular Degeneration

Arlington, Texas
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

140 Participants Needed

HTD1801 for Non-alcoholic Fatty Liver Disease

Arlington, Texas
This trial is testing HTD1801, a medication, to see if it can help adults with NASH and liver fibrosis who also have type 2 diabetes or pre-diabetes. The goal is to see if the medication can reduce liver inflammation and scarring, thereby improving liver health.

Trial Details

Trial Status:Completed
Trial Phase:Phase 2

218 Participants Needed

HM15211 for Non-alcoholic Steatohepatitis (NASH)

Arlington, Texas
This trial is testing a medication called HM15211 to see if it can help people with a liver disease called NASH. The study will check if the medication is safe and effective over a period of time.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

215 Participants Needed

1...345...8

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Arlington, TX pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Arlington, TX work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Arlington, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Arlington, TX is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Arlington, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Arlington, TX?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Arlington, TX?

Most recently, we added Pumitamig + Chemotherapy for Colorectal Cancer, Zasocitinib for Hidradenitis Suppurativa and Dapagliflozin + Baxdrostat for Chronic Kidney Disease to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards in Arlington, TX?

The clinics in Arlington, TX currently recognized as Power Preferred are: North Texas Clinical Trials in Fort Worth, Texas North Texas Clinical Trials in Fort Worth, Texas

Popular Searches

By Condition

Depression Clinical Trials in Texas

Anxiety Clinical Trials in Texas

Schizophrenia Clinical Trials in Texas

ADHD Clinical Trials in Texas

Bipolar Disorder Clinical Trials in Texas

Multiple Sclerosis Clinical Trials in Texas

Autism Clinical Trials in Texas

Treatment Resistant Depression Clinical Trials in Texas

Borderline Personality Disorder Clinical Trials in Texas

Social Anxiety Disorder Clinical Trials in Texas

Parkinson's Disease Clinical Trials in Texas

Alzheimer's Disease Clinical Trials in Texas

By Location

Clinical Trials near Houston, TX

Clinical Trials near Dallas, TX

Clinical Trials near San Antonio, TX

Clinical Trials near Austin, TX

Clinical Trials near Fort Worth, TX

Clinical Trials near Plano, TX

Clinical Trials near Tyler, TX

Clinical Trials near El Paso, TX

Clinical Trials near Lubbock, TX

Clinical Trials near Galveston, TX

Clinical Trials near Temple, TX

Clinical Trials near Arlington, TX

Other People Viewed

By Subject

205 Clinical Trials near Arlington Heights, IL

46 Psoriasis Trials near Dallas, TX

214 Clinical Trials near Garland, TX

40 Psoriasis Trials near Austin, TX

210 Clinical Trials near Carrollton, TX

194 Clinical Trials near Georgetown, TX

175 Clinical Trials near Edinburg, TX

184 Clinical Paid Trials near Houston, TX

218 Clinical Trials near Bryan, TX

Top Clinical Trials near Arlington, VA

Top Clinical Trials near Beaumont, TX

Top Clinical Trials near Amarillo, TX

By Trial

Rezpegaldesleukin for Alopecia Areata

Ritlecitinib for Alopecia Areata

Lutikizumab for Hidradenitis Suppurativa

Inclisiran for Coronary Artery Disease

Deucravacitinib for Dermatomyositis

PF-06651600 for Alopecia Areata

Platelet-rich Plasma Therapy for Hair Loss

Gene Therapy for Duchenne Muscular Dystrophy

Cabozantinib for Rare Cancers in Young Patients

Benralizumab for COPD

CAM2029 for Polycystic Liver Disease

Communication & Screening Intervention for Lung Cancer

Related Searches

Top Clinical Trials near Armonk, NY

Top Clinical Trials near Artesia, CA

Chondro-Gide® for Knee Cartilage Injury

Microneedling and Serum for Acne

Renal Artery Denervation for High Blood Pressure

Zanubrutinib + Rituximab for Chronic Lymphocytic Leukemia

Top Clinical Trials near Clinton, SC

DC-806 for Plaque Psoriasis

Geriatric Assessment for Cancer in Seniors with Frailty or Cognitive Impairment

Ketone Monoester for Hormonal Imbalance After Resistance Training

Top Anorexia-nervosa Clinical Trials

Near Infrared Stimulation for Parkinson's Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial